Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital

O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status has been considered a prognostic factor in newly diagnosed glioblastoma (GBM). In this study, we evaluated the prognostic and predictive value of MGMT promoter methylation in patients with glioblastoma in Donostia Hospital....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Egaña, Larraitz, Auzmendi-Iriarte, Jaione, Andermatten, Joaquin, Villanua, Jorge, Ruiz, Irune, Elua-Pinin, Alejandro, Aldaz, Paula, Querejeta, Arrate, Sarasqueta, Cristina, Zubia, Felix, Matheu, Ander, Samprón, Nicolas
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7595088/
https://ncbi.nlm.nih.gov/pubmed/33116181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-75477-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars